Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trivalent Salmonella Conjugate Vaccine phase 2 trial
PACTR202309532820945Phase 2Recruiting
- Sponsor
- University of Maryland College Park
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised trial of trivalent salmonella conjugate vaccine and typhoid conjugate vaccine in nontyphoidal salmonellosis, typhoid fever and invasive non-typhoidal salmonellosis (iNTS) (4 arms), sponsored by University of Maryland College Park. Primary endpoints: Immediate safety and reactogenicity after immunization, Short-term safety and reactogenicity over 7 days and 6 more. Started Sep 2023; status: recruiting.
02
Drugs
trivalent salmonella conjugate vaccinetyphoid conjugate vaccine
03
Conditions
nontyphoidal salmonellosistyphoid feverinvasive non-typhoidal salmonellosis (iNTS)
Beyond the preview
Go deeper on PACTR202309532820945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202309532820945.